{"corpus_id":3807929,"paper_sha":"d9970a6d9b97c11c7f9014bfb160d2328dac9192","doi":"10.1016/j.jprot.2018.03.004","arxiv_id":null,"pmid":29518575,"pmcid":null,"mag_id":2792456478,"dblp_id":null,"acl_id":null,"title":"Predictive biomarkers for type 2 of diabetes mellitus: Bridging the gap between systems research and personalized medicine.","year":2018,"publication_date":"2018-09-01","venue":"Journal of Proteomics","journal":{"name":"Journal of proteomics","pages":"\n          59-62\n        ","volume":"188"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":44,"citation_count":18,"influential_citation_count":1,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Biomarkers","mj":false,"qs":[{"q":"analysis","mj":false,"ui":"Q000032"}],"ui":"D015415"},{"d":"Diabetes Mellitus, Type 2","mj":false,"qs":[{"q":"diagnosis","mj":true,"ui":"Q000175"},{"q":"prevention & control","mj":false,"ui":"Q000517"},{"q":"therapy","mj":false,"ui":"Q000628"}],"ui":"D003924"},{"d":"Early Diagnosis","mj":false,"ui":"D042241"},{"d":"Genomics","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D023281"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Metabolomics","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D055432"},{"d":"Proteomics","mj":false,"qs":[{"q":"methods","mj":false,"ui":"Q000379"}],"ui":"D040901"}],"chemicals":[{"n":"Biomarkers","ui":"D015415","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"The global incidence of metabolic disorders like type 2 diabetes mellitus (DM2) has assumed epidemic proportions, leading to adverse health and socio-economic impacts. It is therefore of critical importance the early diagnosis of DM2 patients and the detection of those at increased risk of disease. In this respect, Precision Medicine (PM) is an emerging approach that includes practices, tests, decisions and treatments adapted to the characteristics of each patient. With regard to DM2, PM manages a wealth of \"omics\" data (genomic, metabolic, proteomic, environmental, clinical and paraclinical) to increase the number of clinically validated biomarkers in order to identify patients in early stage even before the prediabetic phase.\n\n\nSIGNIFICANCE\nIn this paper, we discuss the epidemic dimension of metabolic disorders like type 2 diabetes mellitus (DM2) and the urgent demand for novel biomarkers to reduce the incidence or even delay the onset of DM2. Recent research data produced by \"multi-omics\" technologies (genomics/epigenomics, transcriptomics, proteomics and metabolomics), suggest that many potential biomarkers might be helpful in the prediction and early diagnosis of DM2. Predictive, Preventive and Personalized Medicine (PPPM) manages and integrates these data to apply personalized, preventive, and therapeutic approaches. This is significant because there is an emerging need for establishing channels for communication and personalized consultation between systems research and precision medicine, as the medicine of the future.","claims":[{"public_id":"cl_5c23bd218a224ff6da182f546c35fc4f","status":"active","text":"Channels for communication and personalized consultation between systems research and precision medicine are needed to advance personalized, preventive, and therapeutic approaches.","confidence":0.8,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_5c23bd218a224ff6da182f546c35fc4f"},{"public_id":"cl_77da0eb6fd6a3fd31ae95c6faeb22c2d","status":"active","text":"Multi-omics data suggest that many potential biomarkers may help predict and diagnose type 2 diabetes mellitus at an early stage.","confidence":0.91,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_77da0eb6fd6a3fd31ae95c6faeb22c2d"},{"public_id":"cl_433c0a44203171fda1ceb949ed5e913e","status":"active","text":"Precision Medicine and Predictive, Preventive and Personalized Medicine integrate genomic, metabolic, proteomic, environmental, clinical, and paraclinical data to increase the number of clinically validated biomarkers for early identification of at-risk patients.","confidence":0.89,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_433c0a44203171fda1ceb949ed5e913e"},{"public_id":"cl_adc0c233058bd8cd1e121cb5238a9611","status":"active","text":"There is an urgent need for novel biomarkers to reduce the incidence of type 2 diabetes mellitus or delay its onset.","confidence":0.84,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_adc0c233058bd8cd1e121cb5238a9611"}],"concepts":[{"public_id":"co_35f7b9740b1e014efe05cbbae3840859","status":"active","name":"clinically validated biomarkers","description":"Biomarkers that have been confirmed for clinical use through validation studies.","types":["biomarker","clinical measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_35f7b9740b1e014efe05cbbae3840859"},{"public_id":"co_3aa20c82a6fe4ddf71adf0f47d8403f6","status":"active","name":"systems research","description":"Research that studies complex biological or medical systems using integrative approaches.","types":["research area"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3aa20c82a6fe4ddf71adf0f47d8403f6"},{"public_id":"co_51f38ebbf738a47571d76a8460025efb","status":"active","name":"multi-omics technologies","description":"Technologies that generate and combine data from multiple biological layers such as genomics, transcriptomics, proteomics, and metabolomics.","types":["technology","data source"],"aliases":["omics technologies"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_51f38ebbf738a47571d76a8460025efb"},{"public_id":"co_5a28cda852175437fda3d8fc92251316","status":"active","name":"novel biomarkers","description":"Newly proposed biological markers that are being investigated for disease prediction or diagnosis.","types":["candidate biomarker"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5a28cda852175437fda3d8fc92251316"},{"public_id":"co_7b0b27d5c454419197010f4be146a701","status":"active","name":"type 2 diabetes mellitus","description":"A metabolic disorder characterized by insulin resistance and chronic hyperglycemia.","types":["disease"],"aliases":["DM2","T2DM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7b0b27d5c454419197010f4be146a701"},{"public_id":"co_ab930638b28daeca7d2fc3dc1443411e","status":"active","name":"Precision Medicine","description":"An approach that adapts tests, decisions, and treatments to the characteristics of each patient.","types":["medical approach"],"aliases":["PM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ab930638b28daeca7d2fc3dc1443411e"},{"public_id":"co_c4a1532379dfd314499fa6cd7232a32c","status":"active","name":"genomic, metabolic, proteomic, environmental, clinical and paraclinical data","description":"A heterogeneous set of biological, environmental, and clinical data used to characterize patients in precision medicine.","types":["data"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c4a1532379dfd314499fa6cd7232a32c"},{"public_id":"co_c5faa01086270ef2dde8f5da60e6d081","status":"active","name":"biomarkers","description":"Measurable biological indicators used to detect or predict disease state or risk.","types":["measure","concept"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c5faa01086270ef2dde8f5da60e6d081"},{"public_id":"co_c611d880c257fd314c96ab4f2465c9f7","status":"active","name":"personalized consultation","description":"Patient-specific consultation tailored to individual biological and clinical characteristics.","types":["clinical practice"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c611d880c257fd314c96ab4f2465c9f7"},{"public_id":"co_ffe957ac400e01e4c8c58df85e4b56cc","status":"active","name":"Predictive, Preventive and Personalized Medicine","description":"A medicine framework that integrates data to support prediction, prevention, and individualized care.","types":["medical approach"],"aliases":["PPPM"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ffe957ac400e01e4c8c58df85e4b56cc"}],"external_ids":{"DOI":"10.1016/j.jprot.2018.03.004","ArXiv":null,"PubMed":29518575,"PubMedCentral":null,"MAG":2792456478,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/3807929","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":638310,"paper_uid":"475bb129-1ca8-425c-bacb-f9777d1e5916","canonical_identity":{"paper_id":638310,"paper_uid":"475bb129-1ca8-425c-bacb-f9777d1e5916","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/3807929"}